Futura Medical plc

Good morning and welcome to the Futura Medical PLC investor presentation. Throughout this quarter presentation, investors will be in this and any mode. Questions are encouraged and they can be submitted at any time by the Q&A tab situated in the right corner of your screen. Just simply type in your questions and press send. The company may not be in a position to answer every question it receives in the meeting itself. However, the company can review all the questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to James Bader, CEO. Good morning to you, sir.

Good morning, everyone, and welcome to Futura Medical's year-end results presentation for the period ending 31st of December 2024. I am James Barlow, CEO of Futura, and I'm joined today by Anja Hildreth, Futura's Finance Director and COO, and also Ken James, Executive Director and Futura's Head of R&D. Futura specializes in the development and commercialization of innovative sexual health products across the world. Our lead product is Roxon, a clinically proven breakthrough treatment for erectile dysfunction. Our key area of expertise is in topically delivered gel formulations. For the last year, I have said consistently that we saw 2024 as a year of execution, and I'm delighted to say this has proved very much the case, with the company delivering on our strategic priorities and in particular growing revenue and our maiden profit. Eroxon is now on sale both online and in retail pharmacies in at least 15 countries, including the USA, with further launches expected during 2025. We continue to see a strong sell-in to retailers through our commercial partners, but as previously mentioned, with any new OTC product launch in a new category, there is an iterative learning process and sales will vary until the brand is established. I will talk more about this later in the presentation. Nevertheless, commercial partners remain committed in building the Aroxon brand. We have also seen excellent progress from Ken and his team for both Iroxon Intents and WSD4000, and Ken will talk more about this shortly. We have also had a strong financial performance, and Andrew will also go into greater detail on this later in the presentation as well.

Thank you, James. So, as a reminder, why is our lead product, Iroxon, a breakthrough, safe and effective First and foremost, it's available without the need of a doctor's prescription. Secondly, we have a unique differentiated claim from the tablets, which helps you get an erection in 10 minutes. Tablets typically take one to two hours before they start to work. Also, it's the first topical gel clinically proven to treat ED available over the counter and linked to that. It's the first FDA-cleared OTC treatment 3D. Move on to the next slide, please. So, Iroxon operates in a market which is currently estimated to be $3.5 billion. Why is it such a big market? Well, around about 20% of men globally suffer from the condition of erectile dysfunction. It's a problem primarily related to the aging process. And it's a sad fact of life that as you get older, things don't work quite so well. And blood flow particularly can become impaired. In some instances, this can ultimately lead to heart disease and diabetes. But very often, the first indicator that blood vessels are narrowing is erectile dysfunction. So, around 50% of men over 40 actually experience ED. But also, it's becoming more and more of a problem in the younger population. And there was a recent study conducted out at Boston, Massachusetts, which showed that around 14% of men aged between 18 and 31 suffer from ED, and 25% of new diagnosis are in men under 40. Also important for our product is that around 50% of men with ED do not discuss their condition with their doctor, often being too embarrassed to present themselves and discuss it. So now I'll hand you back to James again.